Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance

Journal of Immunology

Volumn 177, Issue 12, 2006, Pages 8400-8409

  Iwai, Toshiro ^a   Tomita, Yukihiro ^a,d   Okano, Shinji ^a   Shimizu, Ichiro ^a   Yasunami, Yohichi ^b   Kajiwara, Takashi ^a   Yoshikai, Yasunobu ^a   Taniguchi, Masaru ^c   Nomoto, Kikuo ^a   Yasui, Hisataka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIGEN VBETA6; CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; DONOR; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; MOUSE; MOUSE STRAIN; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; SUPPRESSOR CELL; THYMECTOMY; TRANSPLANTATION TOLERANCE;

EID: 33845391222     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.12.8400     Document Type: Article

References (32)

1. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
2. + NK T cells associated with disease development in autoimmune-prone mice. J. Immunol. 156: 4035-4040.
3. + and CD4+ T cells. J. Immunol. 164: 2009-2015.
4. + αβ T cells in IL-12 production during Salmonella infection. J. Immunol. 163: 2057-2063,
5. Seino, K. I., K. Fukao, K. Muramoto, K. Yanagisawa, Y. Takada, S. Kakuta, Y. Iwakura, L. Van Kaer, K. Takeda, T. Nakayama, et al. 2001. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA 98: 2577-2581.
6. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J. Clin. Invest. 105: 1761-1767.
7. Shin, T., H. Mayumi, K. Himeno, H. Sanui, and K. Nomoto. 1984. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation 37: 580-584.
8. Mayumi, H., T. Shin, K. Himeno, and K. Nomoto. 1985. Drug-induced tolerance to allografts in mice II. Tolerance to tumor allografts of large doses associated with rejection of skin allografts and tumor allografts of small doses. Immunobiology 169: 147-161.
9. Mayumi, H., K. Himeno, T. Shin, and K. Nomoto. 1985. Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 39: 209-215.
10. Mayumi, H., K. Himeno, K. Tanaka, N. Tokuda, J. L. Fan, and K. Nomoto. 1986. Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients. Transplantation 42: 417-422.
11. Tomita, Y., H. Mayumi, M. Eto, and K. Nomoto. 1990. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J. Immunol. 144: 463-473.
12. + T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J. Exp. Med. 171: 97-113.
13. Tomita, Y., Y. Nishimura, N. Harada, M. Eto, K. Ayukawa, Y. Yoshikai, and K. Nomoto. 1990. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J. Immunol. 145: 4026-4036.
14. Eto, M., H. Mayumi, Y. Tomita, Y. Yoshikai, Y. Nishimura, and K. Nomoto. 1990. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J. Immunol. 145: 1303-1310.
15. Zhang, Q. W., H. Mayumi, M. Umesue, Y. Tomita, K. Nomoto, and H. Yasui. 1997. Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells. Transplantation. 63: 1667-1673.
16. Maeda, T., M. Eto, Y. Nishimura, K. Nomoto, and Y. Y. Kong. 1993. Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. J. Immunol. 150: 753-762.
17. Yoshikawa, M., Y. Tomita, T. Uchida, Q. W. Zhang, and K. Nomoto. 1999. Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Transplant. Proc. 31: 898-899.
18. Yoshikawa, M., Y. Tomita, T. Uchida, Q. W. Zhang, I. Shimizu, and K. Nomoto. 1999. Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Transplant. Proc. 31: 1939.
19. Tomita, Y., M. Yoshikawa, Q. W. Zhang, I. Shimizu, S. Okano, T. Iwai, H. Yasui, and K. Nomoto. 2000. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J. Immunol. 165: 34-41.
20. Mayumi, H., K. Nomoto, and R. A. Good. 1988. A surgical technique for experimental free skin grafting in mice. Jpn. J. Surg. 18: 548-557.
21. Tomita, Y., A. Khan, and M. Sykes. 1994. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J. Immunol. 153: 1087-1098.
22. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754.
23. - regulatory cells mediate dominant transplantation tolerance. J. Immunol. 168: 5558-5565.
24. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193: 1311-1318.
25. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168: 1080-1086.
26. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
27. - single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor Vβ family. Proc. Natl. Acad. Sci. USA 89: 6506-6510.
28. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
29. Yoshimoto, T., and W. E. Paul. 1994. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179: 1285-1295.
30. Cui, J., N. Watanabe, T. Kawano, M. Yamashita, T. Kamata, C. Shimizu, M. Kimura, E. Shimizu, J. Koike, H. Koseki, et al. 1999. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J. Exp. Med. 190: 783-792.
31. Burdin, N., L. Brossay, and M. Kronenberg. 1999. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29: 2014-2025.
32. Singh, N., S. Hong, D. C. Scherer, I. Serizawa, N. Burdin, M. Kronenberg, Y. Koezuka, and L. Van Kaer. 1999. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163: 2373-2377.